Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Researchers review potential areas for mRNA vaccine development against pathogenic viruses other than SARS-CoV-2.
Researchers detected a swine influenza A virus (IAV)-infected patient in routine surveillance at the National Influenza Center in Denmark. The detected influenza variant appeared distinct from any variant found previously in Denmark.
The latest WHO report updated up to 30 October 2022 has data categorized by influenza transmission zones, i.e., countries/regions with similar influenza transmission patterns.
Researchers compared cardiac autopsy samples from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive cases with age-matched samples from influenza hemagglutinin 1 neuraminidase 1 (H1N1) cases, non-influenza lymphocytic myocarditis cases, and heart tissue with no inflammation to understand the mechanisms underlying the pathology of the cardiac complications during coronavirus disease 2019 (COVID-19).
Researchers proposed that vaccines targeting the immunosubdominant yet conserved hemagglutinin (HA) stem could trigger broadly neutralizing antibodies (bnAbs) against influenza A viruses.
In a recent study published in the journal Engineering Reports, researchers evaluated the reduction in exposure to airborne viruses in aircraft cabins when mitigation measures such as mask-wearing and leaving the middle seat vacant were adopted to understand strategies to limit the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during air travel.
New research presented this week at ACR Convergence 2022, the American College of Rheumatology's annual meeting, showed that discontinuing methotrexate for one week after seasonal influenza vaccination provided the same seroprotection as a two-week discontinuation period in patients with rheumatoid arthritis.
Influenza infection and hospitalization rates continue to increase at an alarmingly fast and early rate this year.
Researchers examined virus-virus interactions using human lung cells coinfected with two co-circulating respiratory infection-causing viruses, respiratory syncytial virus (RSV) and influenza A virus (IAV).
Respiratory viruses continue to be a leading cause of childhood morbidity and mortality.
Researchers presented an overview of factors influencing emerging infectious diseases. They also highlighted the importance of molecular dynamic (MD) simulations and molecular docking (MDO) analysis for combating these diseases.
A recent study published in the Pulmonary Pharmacology & Therapeutics journal described different inhalation therapeutic agents for treating respiratory viral infections like coronavirus disease 2019 (COVID-19).
While influenza has taken a backseat to COVID-19 over the last 2.5 years, flu season is here again and, with a significant reduction in social distancing, masking and other COVID-prevention measures, we’ll likely see many more cases of the flu this year, experts say.
Researchers evaluated the efficacy of dNS1-RBD, a novel intranasal COVID-19 vaccine.
In a new study, researchers calculated the decrease in vaccine effectiveness due to repeated influenza vaccinations.
If you're an avid reader of science news, you've probably heard of viral proteins such as the COVID-19 spike protein.
In a new study, researchers demonstrated the detection of respiratory infectious diseases using bioelectronic masks.
Scientists have created a face mask that can detect common respiratory viruses, including influenza and the coronavirus, in the air in droplets or aerosols.
A new study explores the contribution of genomic sequencing to the scientific understanding of COVID-19, and on the introduction of global public health measures via the ability to pick up new variants early enough.
In a new study, researchers developed a recombinant bivalent vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses.